Network Meta-Analysis of CAR T-Cell Therapy for the Treatment of 3L+ R/R LBCL After Using Published Comparative Studies

Scientists highlight important differences in clinical outcomes between CAR T-cell therapies. Axi-cel demonstrated improved overall survival compared to tisa-cel and liso-cel, and both axi-cel and liso-cel showed higher response rates compared to tisa-cel.